|
業務類別
|
-- |
|
業務概覽
|
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States. |
| 公司地址
| 170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 650 550-3500 |
| 傳真號碼
| +1 650 871-8580 |
| 公司網頁
| https://www.vaxart.com |
| 員工數量
| 105 |
| Mr. James F. Cummings |
Chief Medical Officer |
美元 488.09K |
10/04/2025 |
| Mr. Steven Lo |
Director, President and Chief Executive Officer |
美元 473.81K |
10/04/2025 |
| Dr. Sean N. Tucker, PhD |
Senior Vice President and Chief Scientific Officer |
美元 446.27K |
10/04/2025 |
| Mr. Jeroen Grasman |
Chief Financial Officer and Principal Accounting Officer |
-- |
13/05/2025 |
| Mr. Edward B. Berg |
Senior Vice President and General Counsel |
-- |
10/04/2025 |
|
|
| Mr. Steven Lo |
Director, President and Chief Executive Officer |
10/04/2025 |
| Dr. Michael J. Finney, PhD |
Chairman of the Board |
10/04/2025 |
| Dr. David E. Wheadon, M.D. |
Lead Independent Director |
10/04/2025 |
| Dr. Elaine J. Heron, M.B.A.,PhD |
Independent Director |
10/04/2025 |
| Mr. Kevin P. Finney |
Independent Director |
28/01/2025 |
| Mr. W. Mark Watson |
Independent Director |
10/04/2025 |
|
|
|
|
